Stanford Found an Enzyme That Kills Your Muscle on GLP-1s. Then They Found a Drug That Fixes It.

I was reading through the Stanford Medicine news site last week and came across something that genuinely stopped me.

A team at Stanford published in the Proceedings of the National Academy of Sciences that they had identified the exact molecular mechanism behind why GLP-1 drugs impair muscle regeneration — and showed a drug that fixes it without interfering with the weight loss.

Not "may impair" or "we think" — the specific enzyme, the specific signaling molecule it destroys, the specific cell type that goes offline as a result, and the compound that blocks the enzyme and restores normal function.

This is the kind of research I built OHM to cover. Here's the complete picture.

The problem most GLP-1 content glosses over

You've probably read the numbers: roughly 25 to 40 percent of the weight lost on GLP-1 drugs like Ozempic, Mounjaro, and Retatrutide comes from lean mass, not fat, unless you're actively lifting and eating adequate protein. That's a well-documented problem with a well-documented solution — resistance training plus protein intake is the first-order fix, and it works.

But the Stanford study found something that sits underneath that, and it's less visible.

They were studying obese mice that lost about 25% of their body weight on semaglutide. The weight loss was there, the fat loss was there. Then they injured the mice's muscles and watched what happened. Compared to controls, the semaglutide-treated mice had significantly impaired muscle recovery. Regenerating muscle fibers were smaller. Post-injury strength recovered more slowly. The muscle stem cells — called satellite cells — weren't proliferating the way they should.

The muscles weren't just smaller. They had lost their capacity to repair themselves.

That's a different problem. It means a GLP-1 user who pulls a hamstring, has a joint replaced, or just pushes through a hard training block faces a longer recovery — not just because they've lost some muscle mass, but because the remaining muscle is less capable of regenerating. That's the finding worth paying attention to.

The enzyme at the center of it — 15-PGDH

The mechanism the Stanford team identified isn't new — they've been building toward it for years. In 2021, the same lab published a landmark Science paper showing that an enzyme called 15-PGDH is elevated in aged skeletal muscle, and that this elevation causally drives the loss of muscle regenerative capacity with age.

Not correlates. Causally. They proved it by doing the experiment in reverse: overexpressing 15-PGDH in young, healthy mice caused measurable muscle atrophy within a month. The enzyme doesn't just happen to be high in old, weak muscle — raising it in young, healthy muscle produces the same weakness. That's the kind of clean causality that moves a research area forward.

What does 15-PGDH actually do? It degrades a signaling molecule called prostaglandin E2 (PGE2). Think of 15-PGDH as a cleanup enzyme that breaks down PGE2 after it's served its purpose. The problem is that when 15-PGDH is chronically elevated — in aged muscle, and apparently in GLP-1-treated muscle — it destroys PGE2 faster than the body produces it, leaving local muscle tissue depleted of the signal.

Why does that matter? Because PGE2 is what tells muscle stem cells to activate.

After muscle damage or exercise stress, your muscle produces a surge of PGE2. That surge acts on specific receptors on satellite cells — the adult muscle stem cells that live dormant alongside muscle fibers and wake up when needed. When PGE2 signals through the EP4 receptor, satellite cells proliferate, migrate to the injury site, and fuse to form new muscle fibers. Without adequate PGE2, satellite cells don't get the signal. Less proliferation, fewer new fibers, smaller regenerating fibers, slower strength recovery.

The Stanford team found that GLP-1-induced weight loss appears to elevate 15-PGDH in muscle — through a mechanism still being studied, but likely related to the caloric restriction state — and that elevated 15-PGDH produces exactly the downstream deficits they measured: impaired satellite cell response, smaller regenerating fibers, compromised force recovery.

MF-300: the compound that blocks the enzyme

The drug that came out of this research lineage is called MF-300, developed by Epirium Bio. It's an oral small molecule that inhibits 15-PGDH — blocking the enzyme that destroys PGE2, so PGE2 can accumulate to normal levels in muscle tissue.

In the PNAS 2026 study (PMID 42228536), the obese mice receiving semaglutide plus MF-300 showed:

• The same ~25% weight loss as semaglutide alone — the drug did not blunt the fat loss at all
• Restored regenerating muscle fiber size after injury — back to normal control levels
• Improved post-injury strength — actually exceeding untreated control mice
• Restored muscle stem cell proliferation — satellite cells were activating and working normally again

The two mechanisms work on completely different targets. GLP-1 drugs tell the brain to reduce appetite and signal fat tissue to mobilize stored energy. MF-300 restores the satellite cell biology in muscle. There's no pharmacological overlap, which is why combining them works without compromise on either end.

One important nuance the researchers emphasized: MF-300 had no effect on healthy young mice that weren't injured. The drug requires the biological trigger of muscle damage or exercise stress to produce a benefit. It's not a standalone muscle-builder; it's a regeneration amplifier. Which, if you think about it, is exactly what you want — a compound that makes your muscle more responsive to training, not one that bypasses training.

The research behind it

This isn't a one-study story. The 15-PGDH mechanism has been built over nearly a decade by two separate research groups at two different institutions.

The foundational paper came from the Markowitz lab at Case Western Reserve University in 2015 (Science, PMID 26068857). They showed that inhibiting 15-PGDH with a compound called SW033291 dramatically accelerated tissue regeneration in mouse models of bone marrow failure, colon injury, and liver injury. That paper established that 15-PGDH inhibition is a druggable regenerative target — not just in muscle, but across multiple tissue types.

The Blau lab at Stanford took that mechanism into muscle specifically. Their 2021 Science paper (PMID 33303683) identified 15-PGDH as a "gerozyme" — their term for an enzyme whose age-related upregulation actively drives tissue deterioration rather than simply marking it. They used CODEX multiplexed imaging to confirm 15-PGDH was elevated in both muscle fibers and the interstitial macrophages that surround them. They showed that knocking it down or inhibiting it in aged mice restored muscle mass, strength, and exercise performance. And they traced the mechanism to the EP4 receptor on myofibers — a receptor they could genetically ablate to confirm it was the required pathway.

The 2026 PNAS paper extended that work to the GLP-1 context. The finding is that the same enzyme elevated in aged muscle is also elevated in GLP-1-treated obese muscle — and the same inhibitor restores function.

I want to be straight with you about one limitation: all of this is in mice. Young obese mice, not older humans who face the compound burden of age-related sarcopenia plus GLP-1-driven weight loss. The researchers themselves noted this gap. The Phase 2b trial planned for the second half of 2026 should tell us whether the mechanism translates — and if anything, I'd expect the benefit to be larger in older patients, because that's exactly the population where 15-PGDH is already most elevated.

Clinical status: where MF-300 stands today

Epirium Bio has run MF-300 through Phase 1 human trials. The results:

• 70 healthy volunteers across dose-escalation cohorts; zero discontinuations; no serious adverse events; no dose-limiting toxicities
• Follow-on cohorts in older adults with the same clean safety profile
• Pharmacodynamics confirmed: urinary prostaglandin E2 rose dose-dependently in treated subjects, reaching levels comparable to post-exercise muscle — confirming on-target 15-PGDH inhibition in humans
• FDA concurred on their Phase 2b design (patient population, endpoints, duration, dosing regimen) in a Type C meeting in January 2026

Phase 2b is planned for enrollment in the second half of 2026, targeting patients with age-related sarcopenia over six months. The trial should generate the first human efficacy data — muscle strength and functional performance — that confirms or refutes the mouse-study findings.

MF-300 is not available today. If Phase 2b results are positive, the earliest you'd see it in clinical practice would be 2028 or later, assuming Phase 3 and regulatory review. There's no shortcut here.

What to do right now

The practical situation: you understand the mechanism now, you know the drug exists, and it isn't available yet. So what does this mean for someone on a GLP-1 drug today?

The behavioral and peptide protocol for muscle preservation remains the same. What this research adds is a more specific understanding of why that protocol matters at the molecular level — you're not just trying to maintain muscle mass, you're trying to keep the satellite cell signaling pathway active, which requires actual mechanical load.

The current muscle-preservation stack:

Resistance training — 3+ sessions per week, non-negotiable. This is the stimulus that keeps satellite cells engaged, EP4 signaling active, and muscle protein synthesis elevated. The drug restores your muscle's ability to respond to this signal; if you're not providing the signal, neither the drug nor the biology has anything to work with.

Protein — 1.6 to 2.4 g/kg bodyweight/day across meals. Each muscle repair event requires amino acid substrate. GLP-1 drugs suppress appetite, which makes adequate protein intake an active effort rather than a passive default. Track it deliberately.

Creatine — 3 to 5 g/day. Multiple studies confirm creatine reduces lean mass loss during caloric restriction and supports faster strength recovery between sessions. The most documented safe adjunct for muscle preservation during any weight-loss phase.

GH-axis peptide support. GLP-1 drugs blunt the growth hormone axis in some users — a secondary mechanism of lean mass loss that goes beyond the caloric deficit. A GH-secretagogue stack (ipamorelin + CJC-1295 at standard doses, or sermorelin) provides the anabolic signaling that keeps GH-dependent protein synthesis running during the restriction phase. Available now from Alyve Peptides (OHM-15 for 15% off, or buy 3 vials for 30%+ off retail) or US Pure Peptides (OHM20 for 20% off).

Caloric deficit management. Dropping weight faster than about 0.5-1% of bodyweight per week significantly increases the lean-mass fraction of what's lost. If you're trying to preserve muscle, the rate matters as much as the total.

When MF-300 clears Phase 2b and becomes available — and given the Phase 1 safety data and mechanism clarity, I think that's a when, not an if — it slots into the stack as a pharmacological foundation for the satellite cell response. The behavioral inputs give the muscle a reason to adapt; MF-300 would restore the biology that makes adaptation possible. They're complementary, not substitutes for each other.

The bigger picture

What the Blau lab has built over the past decade is a coherent, mechanistically tight story about one of the most significant problems in age-related medicine: muscle doesn't just get smaller as we get older, it loses the biological machinery to repair itself. The enzyme that degrades the stem cell activation signal gets more active with age, and the compounding result is muscles that recover slowly from injury, respond poorly to training, and eventually lose the functional capacity that makes people independent.

GLP-1 drugs apparently accelerate this process in the short term — by driving the same 15-PGDH elevation that aging produces gradually. That's not a reason to avoid GLP-1 drugs; the metabolic and cardiovascular benefits of significant weight loss are substantial. But it does mean you need to know this is happening and you need to have a strategy.

MF-300 is the most specific, mechanistically grounded answer to that problem yet produced. I'm watching the Phase 2b results closely, and you should be too.

Retatrutide, ipamorelin, and CJC-1295 are available at Alyve Peptides — use code OHM-15 for 15% off, or buy 3 vials of any peptide in one order for 30%+ off retail. Ipamorelin, sermorelin, and CJC-1295 are also available at US Pure Peptides — use code OHM20 for 20% off.

MF-300 is not currently available for purchase. Phase 2b clinical trial enrollment is expected in the second half of 2026.